Kernal Biologics
YC S20Boston, US · 20 employees · 4 known investors
Kernal Bio is a synthetic biology company developing selective mRNA drugs to treat serious illnesses, with a focus on cancer therapeutics and improving patient outcomes.
AI & Machine LearningBiotechHealthtechMedical DevicesArtificial IntelligenceGenomicsin /kernal-biologics-inc./@kernalbio
Founders & leadership· Y Combinator alumni (S20)
Yusuf Erkulin𝕏Chief Executive Officer & Cofounder
Jeff OzdemirinHead of Platform & Cofounder
Burak YILMAZinFounder
BY
Burak YilmazPresident & Cofounder
Investors · 4
In the news
- Kernal Biologics to Showcase mRNA 2.0 Platform and T-Cell-Targeted LNPs for In Situ CAR T Programming at ASGCT 2026 - BioSpacebiospace.com · 2026
- ARPA-H invests in Kernal's mRNA cell therapyfiercebiotech.com · 2025
- Biotech startup Kernal Biologics received a $48 millionforbes.com · 2025
- Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapiesfinance.yahoo.com · 2025
- Kernal Biologics Announces $25M Series A Financing to Advance its mRNA 2.0 Technology for Oncologyprnewswire.com · 2022
- Kernal Biologics Raises $25M Series A Financingfinsmes.com · 2022
- Amgen-backed Kernal Biologics pops off with $25M for mRNA platformfiercebiotech.com · 2022
- Kernal Biologics - 2025 Funding Rounds & List of Investors - Tracxntracxn.com · 2021